Vaccine News and Research

Latest Vaccine News and Research

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Researchers tested the antibodies elicited from mRNA vaccination and compared them to those from natural SARS-CoV-2 infection. They found the vaccine did not have antibodies to the virus nucleocapsid protein but had potent RBD antibodies.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Researchers in the UK have conducted a study that may explain why children who become infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not generally develop severe coronavirus disease 2019 (COVID-19).

20 Apr 2021

Study explores how lessons from past crises could improve the pandemic response

The lack of accountability, poor communication and insufficient planning plaguing the government’s response to the COVID-19 pandemic -- especially in its early months -- have roots in how the nation responded to 9/11, Hurricane Katrina and the H1N1 swine flu, a new study involving the University of Washington found.

20 Apr 2021

Chronic SARS-CoV-2 infections favor viral adaptation, says study

A new study offers a look at how to keep these hopes alive in the current context of highly infectious variants, which often display immune escape mutations.

20 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral diseases, emphasizing its importance in SARS-CoV-2 vaccine discovery.

20 Apr 2021

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study published in Frontiers in Immunology.

20 Apr 2021

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Opioid addicts wage a daily war within over whether or not to use a drug whose side effect can be death. If those same addicts, however, had the choice to take an opioid vaccine once or twice a year, their internal struggle could be over.

20 Apr 2021

New machine-learning program accurately identifies COVID-19 conspiracy theories on social media

A new machine-learning program accurately identifies COVID-19-related conspiracy theories on social media and models how they evolved over time--a tool that could someday help public health officials combat misinformation online.

20 Apr 2021

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Ensuring COVID-19 vaccine access for refugee and displaced populations, and addressing health inequities, is vital for an effective pandemic response.

20 Apr 2021

Updated insights for safe COVID-19 vaccination in patients with reported allergic reactions

At the end of 2020, experts led by allergists at Massachusetts General Hospital examined all information related to possible allergic reactions to COVID-19 vaccinations.

19 Apr 2021

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

CoronaVac is a well-tolerated vaccine containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and it induced humoral responses in phase 1 and 2 studies. Analysis of a Brazilian phase 3 clinical trial that evaluated 12,607 participants showed that the vaccine had an efficacy of 50.39% 15 days after the 2nd dose.

19 Apr 2021

Study identifies COVID-19 vaccine inequity in Massachusetts

A new study led by Bisola O. Ojikutu of Brigham and Women’s Hospital in Boston suggests not only do these communities have a higher infection, but they are also experiencing lower vaccine distribution. The team suggests that reformation for equitable vaccine delivery is necessary to eliminate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Majority of Americans support COVID-19 vaccine mandates, study finds

As vaccines that help protect against COVID-19 become available for more people across the United States, questions have been raised about whether institutions like schools and universities should require their students and staff to become vaccinated.

19 Apr 2021

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

Vaccine News and Research

Latest Vaccine News and Research

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Study explores how lessons from past crises could improve the pandemic response

Chronic SARS-CoV-2 infections favor viral adaptation, says study

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

New machine-learning program accurately identifies COVID-19 conspiracy theories on social media

Despite global efforts, allocation and distribution of COVID-19 vaccines are not equitable

Updated insights for safe COVID-19 vaccination in patients with reported allergic reactions

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

Study identifies COVID-19 vaccine inequity in Massachusetts

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Majority of Americans support COVID-19 vaccine mandates, study finds

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers manufacture the SARS-CoV-2 RBD in pichia

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in